胡椒碱通过Apelin 13调控AMPK/PGC-1α通路改善缺血性脑损伤
本研究探讨胡椒碱联合Apelin 13对缺血性脑卒中后线粒体生物合成的影响及机制。采用网络药理学筛选、大鼠pMCAO模型和原代皮层神经元氧糖剥夺再灌注模型,发现胡椒碱可促进Apelin 13表达,经AMPK/PGC-1α通路激活线粒体生物合成,减轻线粒体功能损伤,发挥神经保护作用。
要点
- 胡椒碱可上调Apelin 13,激活AMPK/PGC-1α通路促进线粒体生物合成。
- 胡椒碱与Apelin 13联用对缺血性脑损伤的神经保护作用更显著。
- 敲低Apelin 13可阻断胡椒碱的上述保护效应。
核心结论
- 胡椒碱通过促进Apelin 13调控AMPK/PGC-1α通路激活线粒体生物合成,减轻缺血性脑损伤线粒体功能损伤。
研究设计与样本
- 采用网络药理学筛选缺血性脑卒中组合治疗药物,并使用雄性Sprague-Dawley大鼠诱导pMCAO模型及原代皮层神经元氧糖剥夺再灌注模型。
- 通过siRNA敲低原代皮层神经元Apelin 13以探究胡椒碱促进Apelin 13调控AMPK/PGC-1α通路的机制。
主要发现
- 网络药理学结果显示Apelin 13影响缺血性脑卒中,胡椒碱联合Apelin 13对缺血性脑卒中发挥神经保护作用。
- 与Con组比较,OGD/R组线粒体膜电位降低、活性氧水平升高、ATP含量下降,提示明显线粒体功能损伤。
- 与OGD/R组比较,胡椒碱组和Apelin 13组线粒体功能检测及线粒体生物合成相关因子表达水平显著改善,两者联用神经保护作用更显著。
- 体内外实验显示,与正常组比较模型组Apelin 13 mRNA和蛋白表达显著降低;与模型组比较胡椒碱组Apelin 13丰度显著升高。
- si-Apelin 13敲低Apelin 13后有效阻断了胡椒碱和Apelin 13单用乃至联用的效应。
临床怎么用
- 胡椒碱作为中药活性成分,可能通过Apelin 13-AMPK/PGC-1α-线粒体生物合成轴为缺血性脑卒中提供候选干预靶点。
- 联合Apelin 13可能增强胡椒碱的神经保护效应,但临床转化前需进一步验证。
局限性
- 研究仅使用雄性Sprague-Dawley大鼠pMCAO模型和原代皮层神经元氧糖剥夺再灌注模型,结论外推至临床需谨慎。
- 未报告样本量、具体剂量、P值及置信区间等定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ischemic stroke (IS) persists as the second foremost cause of mortality and the primary cause of long-term disability globally, a burden largely attributable to a paucity of effective therapeutic strategies. Piperine (PIP) is a bioactive component of traditional Chinese medicine that has shown potential to reduce cell inflammation and pyroptosis. Recent studies indicate that mitochondrial biogenesis can improve ischemic stroke. OBJECTIVE: In this study, we aimed to investigate the effect of PIP combined with Apelin 13 on mitochondrial biosynthesis in IS and determine its mechanism and whether PIP promotes Apelin 13. METHODS: We used network pharmacology to screen chemical drugs for combination therapy for IS. Male Sprague-Dawley rats were utilized to induce a model of pMCAO, and primary cortical neuron cells were extracted to establish an oxygen-sugar deprivation-reperfusion model. To evaluate the changes in mitochondrial function of neuronal cells, we observed mitochondrial membrane potential via fluorescence microscopy, detected ROS levels by flow cytometry, and determined the ATP concentration by using a chemiluminescence multifunctional microplate reader. Western blot and qRT-PCR were used to detect the protein expression and mRNA content of Apelin 13 and the AMPK/PGC-1α pathway. In addition, the underlying mechanism of action of PIP promoting Apelin 13 in the regulation of the AMPK/PGC-1α pathway by using siRNA to reduce the content of Apelin 13 in primary cortical neurons was investigated. RESULTS: The results of network pharmacology research indicated that Apelin 13 affects IS. PIP combined with Apelin 13 exerts neuroprotective effects against IS. The OGD/R group showed obvious mitochondrial functional damage, reduced mitochondrial membrane potential, increased reactive oxygen species level, and decreased ATP content compared with the Con group. Compared with the OGD/R group, the mitochondrial function detection and expression level of mitochondrial biogenesis-related factors in the PIP and Apelin 13 groups significantly improved, and the neuroprotective effect was more significant when the two were combined. Our in vitro and in vivo experiments revealed that, compared with the normal group, the mRNA and protein expression of Apelin 13 in the model group significantly decreased. Furthermore, the abundance of Apelin 13 in the PIP group substantially rose compared with that in the model group. When the expression of Apelin 13 was knocked down by si-Apelin 13, si-Apelin 13 effectively blocked the individual or even combined effects of PIP and Apelin 13. CONCLUSION: This study showed that PIP could promote Apelin 13 to activate mitochondrial biogenesis and decreased mitochondrial functional damage. The potential mechanism of activating mitochondrial biogenesis lies in the regulation of the AMPK/PGC-1α pathway. This study not only expands the understanding of the clinical application of PIP in the treatment of IS but also provides new insights into its internal mechanism.
引用
- Xi S, Ma J, Yan J, et al. Piperine improves ischemic brain injury by promoting the regulation of the AMPK/PGC-1α pathway by Apelin 13. Front Pharmacol. 2026. PMID: 41660511. doi:10.3389/fphar.2026.1746901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。